The global human insulin market is projected to reach USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Base year considered for the report is 2014.

Objectives of the study are:

To define, describe, and forecast the global human insulin market on the basis of product, human insulin drugs type, human insulin drugs brand, delivery device, and application

To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, and challenges)

To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market

To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for leading market players

To forecast the size of the market segments with respect to four main regions, namely, North America (U.S. and Canada), Europe (Germany, France, U.K., and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and the Rest of the World

To strategically profile the key market players and comprehensively analyze their market shares and core competencies2

To track and analyze competitive developments such as joint ventures; mergers and acquisitions; new product developments; and partnerships, agreements, and collaborations in the human insulin market

Human Insulin Market : Research Methodology

This research study involved the extensive use of secondary sources, directories, and databases (such as Hoovers, Bloomberg Business, Factiva, and Avention) to identify and collect information useful for this technology-based, market-oriented, and commercial study of the global human insulin market. In-depth interviews were conducted with various primary respondents that mainly included key industry participants, subject-matter experts (SMEs), C & D level executives of key market players, and independent industry consultants, among others; to obtain and verify critical qualitative and quantitative information as well as to assess future market prospects of the global human insulin industry.

The secondary sources referred to for this research study include corporate filings (such as annual reports, SEC filings, investor presentations, and financial statements); research journals; press releases; as well as articles published by various trade, business, and professional associations.

To know about the assumptions considered for the study, download the pdf brochure

In 2014, Novo Nordisk A/S (Denmark) dominated the global human insulin market. Over the past three years, the company adopted product commercialization, geographic expansion, and awareness campaigns as key business strategies to maintain its position in the market. The other key players in this market include Sanofi (France), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Ypsomed AG (Switzerland), Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.), among others.

Stakeholders

Healthcare Service Providers (Including Hospitals, Clinics, and Medical Centers)

Research Laboratories and Academic Institutes

Product Sales and Distribution Companies

Original Equipment Manufacturers (OEMs)

Pharmaceutical and Biotechnology Companies

Clinical Research Organizations (CROs)

Research and Development Companies

Market Research and Consulting Firms

Non-government Organizations

Human Insulin Market : Scope of the Report

This research report categorizes the human insulin market into the following segments and subsegments:

Human Insulin Market, By Product

Drugs

Delivery Devices

Human Insulin Drugs Market, By Product Type

Insulin Analogs and Biosimilars Rapid-acting Long-acting Premixed

Human Insulin Biologics Short-acting Intermediate-acting Premixed



Human Insulin Drugs Market, By Brand

Insulin Analogs and Biosimilars Lantus NovoRapid/Novolog Humalog Other Brands

Human Insulin Biologics Actrapid, Insulatard, and Mixtard Humulin Insuman



Human Insulin Delivery Devices Market, By Product Type

Pens Reusable Disposable

Pen Needles Standard Safety

Syringes

Human Insulin Market, By Region

North America US Canada

Europe Germany UK France Rest of Europe

Asia Pacific Japan China India Rest of Asia Pacific

Rest of the World

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for the report:

Product Analysis

Product matrix which gives a detailed comparison of the product portfolios of the top five companies

Human Insulin Market : Geographical Analysis

Further breakdown of the Rest of Europe human insulin market size into Italy, Spain, Poland, and other countries

Further breakdown of the Rest of Asia-Pacific human insulin market size into Australia, South Korea, Indonesia, and other countries

Further breakdown of the RoW human insulin market size into the Middle East, Latin America, and Africa

Company Information

Detailed analysis and profiling of additional market players (Up to 5)

The global human insulin market is poised to reach ~USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of market. In addition, high product manufacturing costs is posing significant challenges for market growth.

On the basis of product, the human insulin market is classified into two major segments� drugs and delivery devices. Human insulin drugs segment is expected to account for the largest share of the global market, by product, in 2015. Its large share is propelled by factors such as increasing diabetic population across globe, growing R&D for drug discovery & development, rising proportion of aging population in developed countries, increasing market accessibility of generic human insulin products worldwide, and rising government initiatives to support the development and commercialization of effective biosimilars.

On the basis of product type, the human insulin delivery devices market is classified into three segments�pens, pen needles, and syringes. The pens segment is expected to account for the largest market share in 2015; it is poised to be the fastest-growing segment during the next five years. Its high growth can be attributed to growing market focus of pen manufacturers on emerging countries such as China, India, & Brazil; significant medical reimbursements offered for human insulin pens across mature markets such as the U.S. & Europe; and continuous pipeline development & product commercialization of innovative human insulin pens.

Geographically, the market is classified into four regions�North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, North America is estimated to dominate the global human insulin market. The Asia-Pacific market is poised to grow the fastest, during the forecast period, owing to growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, continued expansion of advanced medical facilities in emerging countries (such as China & India), and rising public awareness related to benefits offered by human insulin in diabetes treatment.

Geography expansion and product development are the key strategies adopted by major players to strengthen their positions in the global market. Moreover, strategies such as partnerships, agreements, collaborations, awareness campaigns, and research funding & grants were also adopted by a significant number of market players to strengthen their product portfolios and expand their distribution networks in the global human insulin market.